Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

بواسطة Bakris, George L, Agarwal, Rajiv, Anker, Stefan D, Pitt, Bertram, Ruilope, Luis M, Nowack, Christina, Kolkhof, Peter, Ferreira, Anna C, Schloemer, Patrick, Filippatos, Gerasimos, FIGARO-DKD investigators
منشور في 2023

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

بواسطة Pitt, Bertram, Filippatos, Gerasimos, Agarwal, Rajiv, Anker, Stefan D, Bakris, George L, Rossing, Peter, Joseph, Amer, Kolkhof, Peter, Nowack, Christina, Schloemer, Patrick, Ruilope, Luis M, FIGARO-DKD investigators
منشور في 2023

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes

بواسطة Filippatos, Gerasimos, Bakris, George L., Pitt, Bertram, Agarwal, Rajiv, Rossing, Peter, Ruilope, Luis M., Butler, Javed, Lam, Carolyn S. P., Kolkhof, Peter, Roberts, Luke, Tasto, Christoph, Joseph, Amer, Anker, Stefan D., FIDELIO-DKD Investigators.
منشور في 2022

Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis

بواسطة Anantharaman, Vathsala, Rossing, Peter, Anker, Stefan D, Filippatos, Gerasimos, Pitt, Bertram, Ruilope, Luis M, Birkenfeld, Andreas L, McGill, Janet B, Rosas, Sylvia E, Joseph, Amer, Gebel, Martin, Roberts, Luke, Scheerer, Markus F, Bakris, George L, Agarwal, Rajiv
منشور في 2023